Jyoti Prakash

Brian Adams

- **KRTL Biotech**, a majority-owned subsidiary of KRTL Holding Group Inc., is highlighting its expanded portfolio of **anti-infective and antibiotic products**, developed in collaboration with **SIGMA Corp.**.  **[1010086_9dc4933109f14fc3ac5ce81c18cdd457_0]** 
- The current product line includes essential formulations such as **Hostess Suspension**, **Positrin**, and **Taxonid**, with SIGMA's GMP-certified facility capable of producing a broader range of therapies, including penicillin derivatives and macrolides.  **[1010086_9dc4933109f14fc3ac5ce81c18cdd457_0]** 
- These offerings align with the **World Health Organization's (WHO) Model List of Essential Medicines**, targeting a global anti-infectives market estimated to exceed **$150 billion annually**.  **[1010086_9dc4933109f14fc3ac5ce81c18cdd457_1]** 
- **KRTL Biotech** is evaluating regulatory pathways for select formulations to enter U.S. and other export markets, leveraging **SIGMA's manufacturing capabilities** in Bolivia, which contributed significantly to national pharmaceutical distribution in **fiscal year 2024**.  **[1010086_9dc4933109f14fc3ac5ce81c18cdd457_1]**

SIGA TECHNOLOGIES (SIGA)